Form 4: ENDRA CFO Granted 20,000 Restricted Stock Units

ENDRA Life Sciences Inc.'s Chief Financial Officer, Richard Jacroux, was granted 20,000 restricted stock units, vesting fully on January 21, 2027.

Summary

• Richard Jacroux, Chief Financial Officer of ENDRA Life Sciences Inc. (NDRA), was granted 20,000 restricted stock units (RSUs).
• The transaction date for this grant was January 21, 2026.
• These RSUs convert to common stock on a one-for-one basis.
• The RSUs will vest in full on January 21, 2027.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates ongoing executive compensation and alignment of interests, which is a normal and healthy aspect of corporate governance, without any negative surprises.

Positives

• The grant of restricted stock units to the Chief Financial Officer aligns management's interests with those of shareholders, incentivizing long-term performance.
• The use of a Rule 10b5-1(c) plan indicates a pre-arranged, compliant transaction.

Negatives

• The future conversion of RSUs to common stock will result in minor dilution for existing shareholders.

Future Outlook

NA

Industry Context

The grant of restricted stock units to a key executive like the CFO is a standard practice in the life sciences industry and broader corporate landscape for executive compensation. It serves to attract, retain, and motivate talent by linking their long-term financial incentives to the company's stock performance.

Comparison to Industry Standards

• Executive compensation packages in the life sciences sector frequently include equity components such as restricted stock units (RSUs) to align executive interests with shareholder value creation.
• Companies like Pfizer, Johnson & Johnson, and Moderna commonly utilize RSU grants as a significant part of their executive incentive programs, often with multi-year vesting schedules.
• The 20,000 RSU grant to ENDRA's CFO is a typical mechanism for long-term incentive compensation, comparable in structure to grants observed across similar-sized companies in the medical technology and diagnostics space.

Related Party Transactions

• The grant of 20,000 restricted stock units to Richard Jacroux, the Chief Financial Officer, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Minor potential dilution upon vesting, but also increased alignment of management's interests with long-term shareholder value.
• Employees: May signal stability in executive compensation practices.
• Management: Provides a long-term incentive and compensation component.

Next Steps

• The 20,000 restricted stock units will vest in full on January 21, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and does not provide new information that would fundamentally alter the investment thesis for ENDRA Life Sciences Inc. While it signals management alignment, it's not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should continue to hold and monitor broader company performance and financial disclosures.

Keywords

ENDRA Life Sciences, NDRA, Richard Jacroux, CFO, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Stock Grant, Form 4, Rule 10b5-1